Why Old Muscle Still Listens to Strength

Keywords: Muscle-Centric Medicine, Sarcopenia, Metabolic Aging, Resistance Training, mTOR-Autophagy Axis

Rethinking Muscle Aging in the Era of Longevity Medicine

Sarcopenia is classically defined as a progressive and generalized loss of skeletal muscle mass and strength that begins in mid‑adulthood and accelerates with advancing age, predisposing individuals to physical disability, loss of independence, and death. Epidemiological studies in community‑dwelling and institutionalized older adults report sarcopenia prevalences ranging from approximately 1–29% in general older populations to more than 30–40% in hospitalized or long‑term care cohorts, where it is strongly linked with impaired activities of daily living, longer hospital stays, and higher mortality risk. These observations have firmly established low muscle mass and function as a core geriatric syndrome and a key determinant of morbidity, institutionalization, and survival in very old adults.

Paradoxically, aging muscle that is shrinking and weakening does not always exhibit a simple deficiency of anabolic signalling, but instead can show chronic activation or dysregulation of growth and nutrient‑sensing pathways such as mechanistic target of rapamycin complex 1 (mTORC1) and insulin/insulin‑like growth factor‑1 (IGF‑1) signalling. Experimental work in aging mice and humans demonstrates that subsets of atrophic fibers display elevated mTORC1 activity colocalized with structural damage, mitochondrial abnormalities, oxidative stress, and upregulation of catabolic programs mediated in part by growth differentiation factors and STAT3 signalling. These data support a model in which persistent, low‑grade activation of mTORC1 in the absence of adequate mechanical loading and cellular repair promotes degeneration rather than growth, contributing to the apparent mismatch between “anabolic” signalling and net muscle loss in late life.

Insights from geroscience further highlight lifespan-health span trade-offs along the insulin/IGF-1-mTORaxis, where systemic attenuation of these pathways through genetic manipulation, dietary restriction, or pharmacologic inhibition can extend lifespan in diverse model organisms but may simultaneously reduce growth, reproductive output, and in some contexts compromise muscle integrity. Selective suppression of mTORC1 or translational activity in specific tissues such as muscle has produced complex phenotypes, including altered motility and shortened lifespan when muscle protein synthesis is chronically constrained, underscoring that the benefits of reduced nutrient signalling are highly context‑ and tissue‑dependent. From a clinical standpoint, these findings suggest that the goal in aging muscle is neither maximal suppression nor unchecked activation of anabolic pathways, but rather modulation: sufficient, intermittent activation of mTORC1 and IGF‑1 signalling to support muscle protein synthesis, regeneration, and neuromuscular function, while avoiding chronic overactivation that impairs autophagy, promotes oxidative damage, and accelerates fiber loss. Such a nuanced, context‑specific approach typically combining mechanical loading, adequate protein intake, and avoidance of chronic overnutrition offers a path to reconcile longevity-oriented interventions with the imperative to preserve skeletal muscle mass and function across the lifespan.

Defining the Aging Muscle Paradox

Skeletal muscle is the largest insulin‑sensitive organ in non‑obese adults by mass and serves as the principal site of insulin‑stimulated glucose disposal after carbohydrate ingestion, accounting for roughly 70–80% of glucose uptake under clamp conditions. This dominant contribution positions muscle as a frontline defense against insulin resistance and type 2 diabetes, such that impairments in muscle insulin signalling and glucose transport frequently precede and drive systemic dysglycemia rather than merely reflecting it. In addition to its role in glucose clearance, skeletal muscle stores the majority of body glycogen and functions as a major site of lipid oxidation and amino acid metabolism, making it a central hub in whole‑body energy homeostasis [1,2,3,4,5].

Figure 1. Insulin signaling pathways regulating glucose transport and glycogen synthase in skeletal muscle [4]

Across diverse populations, low muscle mass and reduced muscular strength are consistently associated with an increased burden of cardiometabolic risk factors, higher incidence of cardiovascular disease, and greater all‑cause and cardiovascular mortality. Large cohort studies show that lower handgrip strength and reduced skeletal muscle mass index predict incident diabetes, cardiovascular events, hospitalization, and premature death, independent of traditional risk factors and even after adjusting for physical activity and cardiorespiratory fitness. These findings support the concept of muscle quality, integrating mass, strength, power, and metabolic function as a key determinant of survival and health span, where declines in muscle function signal early erosion of physiological reserve long before overt frailty emerges [6,7,8,9,10].

Geroscience frameworks increasingly interpret aging as a process driven by progressive “metabolaging,” in which metabolic slowdown, mitochondrial dysfunction, and impaired substrate utilization act as proximal causes of functional decline and late‑life disease. Within this network, skeletal muscle occupies a pivotal position: aging‑related reductions in physical activity, hormonal changes, low‑grade inflammation, and inadequate protein intake converge on muscle to produce bioenergetic deficits, insulin resistance, and catabolic remodelling that accelerate systemic aging. Conceptual models that frame metabolic slowdown as a causal driver of aging rather than a passive correlate therefore place preservation and revitalization of skeletal muscle metabolism at the center of strategies to extend health span [8,10].

This emerging evidence base underpins a muscle‑centric medicine framework that reframes skeletal muscle from a cosmetic or performance‑oriented tissue to a core organ of longevity whose integrity shapes the trajectory of metabolic aging. Within such a framework, resistance training, adequate protein intake, and interventions that improve muscle insulin sensitivity are not ancillary lifestyle recommendations but primary therapeutic tools to maintain metabolic resilience and delay the onset of cardiometabolic disease and functional dependency. Preserving and enhancing muscle mass, strength, and metabolic flexibility across adulthood thus becomes a foundational strategy for health span extension, aligning clinical practice with the recognition of skeletal muscle as a true longevity engine rather than merely a locomotor system [2,6,11,12].

Muscle as a Metabolic Organ of Longevity

Mitochondrial dysfunction and impaired mitochondrial quality control represent a third, interconnected mechanism linking metabolic slowdown to local muscle aging and functional decline. Age‑related reductions in mitochondrial respiratory capacity, ATP synthesis, and maximal oxygen consumption are independent of fat‑free mass and correlate tightly with preferred walking speed, a defining criterion for sarcopenia and physical frailty, suggesting that bioenergetic failure directly constrains muscle performance. The underlying pathophysiology involves a vicious cycle of reactive oxygen species (ROS) production, mitochondrial DNA (mtDNA) mutations and damage, impaired mitochondrial biogenesis, and defective mitophagy (selective autophagy of damaged mitochondria), leading to the accumulation of structurally abnormal, dysfunctional mitochondria within aging fibers. Emerging evidence links mitochondrial dysfunction to denervation and fragmentation of the neuromuscular junction, which precedes and accelerates the loss of muscle strength in older adults. Importantly, structured exercise training stimulates both mitochondrial biogenesis, regulated in part by peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a) and mitophagy, thereby restoring mitochondrial turnover and largely negating the effects of aging on muscle oxidative capacity, insulin sensitivity, and physical performance [17,18,19,20,21].

Figure 2. The mechanisms of mitochondrial oxidative stress mediates mitochondrial biosynthesis disorders, inflammation and apoptosis during aging [17]

These mechanistic insights highlight critical trade-offs when targeting nutrient‑sensing pathways for longevity: interventions that extend lifespan by suppressing mTOR, IGF‑1, or caloric intake may simultaneously compromise muscle mass and function if not combined with mechanical loading and adequate protein. Acute pharmacologic inhibition of mTORC1 with rapamycin blocks the contraction‑induced increase in muscle protein synthesis by approximately 40% in humans, demonstrating that mTORC1 activity is essential for exercise‑mediated anabolism in the short term. However, long‑term administration of rapamycin (9–22 months) in aging mice does not reduce muscle mass and in fact mitigates age‑related mitochondrial aging, preserves muscle function, and extends lifespan, with distinct and additive benefits when combined with caloric restriction or exercise training. Importantly, dose matters: low‑dose rapamycin increases muscle cross‑sectional area and preserves fast‑twitch fiber density in aged rats, whereas high‑dose rapamycin offers no such benefit, underscoring the need for context‑specific modulation rather than maximal suppression. Similarly, caloric restriction and protein restriction lower circulating IGF‑1 levels and extend lifespan in rodents, but in humans the effect is largely driven by reduced protein intake rather than total energy restriction, and prolonged severe protein restriction risks muscle loss unless offset by resistance exercise. mechanistically, patterned, intermittent activation of mTORC1 as occurs with resistance exercise which induces rapid translocation of mTOR to the cell membrane, dissociation of inhibitory TSC2 from Rheb, and colocalization with translation initiation factors supports muscle hypertrophy and repair, whereas chronic, unregulated mTOR1 activation in the absence of mechanical stimuli drives oxidative damage and atrophy. From a clinical standpoint, these findings suggest that the goal in aging muscle is neither maximal suppression nor unchecked activation of anabolic pathways, but rather context-specific, intermittent modulation: sufficient mTORC1 and IGF-1 signalling, synchronized with resistance training and adequate protein intake to support muscle protein synthesis, satellite cell function, and neuromuscular integrity, while avoiding chronic overnutrition and sedentary behaviour that promote insulin resistance, mitochondrial dysfunction, and accelerated fiber loss [14,15,22,23,24,25,26,27,28].

Figure 3. Depicts the extracellular and intracellular signaling molecules involved in the cross-talk between skeletal muscle mass regulation and life/health-span modulation [25]

Molecular Mechanisms Behind the Paradox

A paradoxical feature of aging skeletal muscle is that tissue undergoing progressive atrophy does not exhibit a simple deficiency of anabolic signalling; rather, subsets of sarcopenic fibers demonstrate chronic activation or dysregulation of mechanistic target of rapamycin complex 1 (mTORC1) and insulin‑like growth factor‑1 (IGF‑1) pathways, coexisting with suppressed autophagy and impaired protein quality control. Under normal conditions, mTORC1 negatively regulates autophagy by phosphorylating ULK1 at Ser757 and ATG13 at Ser258, thereby blocking autophagosome formation and preventing the recycling of damaged proteins and organelles. Experimental work in aging mice reveals that fibers with elevated mTORC1 activity was detected as increased phosphorylation of ribosomal protein S6 which are colocalized with structural damage, mitochondrial abnormalities, oxidative stress, and upregulation of catabolic programs mediated in part by growth differentiation factors (GDF3, GDF5, GDF15) and phospho‑STAT3. In transgenic mouse models in which mTORC1 is constitutively activated by deletion of Tuberous Sclerosis Complex 1 (TSC1), muscle fibers initially hypertrophy but subsequently undergo progressive fiber damage, atrophy, and death, resulting in approximately 50% fiber loss by 18 months of age, severe kyphosis, and early mortality. Critically, chronic mTORC1 activation in these models blocks both constitutive and fasting‑induced autophagy, leading to age‑dependent accumulation of autophagic vacuoles, cellular debris, and dysfunctional mitochondria, demonstrating that persistent mTORC1 activity in the absence of adequate mechanical loading and autophagic renewal promotes degeneration rather than growth. Conversely, emerging evidence indicates that autophagy is not merely a passive consequence of mTORC1 inhibition but an active contributor to anabolic signalling: pharmacological inhibition of autophagy suppresses mTORC1‑mediated protein synthesis and muscle hypertrophy, suggesting that the relationship between mTORC1 and autophagy is bidirectional, with autophagic proteolysis providing substrates including recycled amino acids, essential for mTORC1 activation and protein synthesis. Exercise training in aged muscle suppresses overactive mTORC1 by downregulating DEAF1, a FOXO‑regulated transcription factor, thereby normalizing the balance between protein synthesis and autophagy and attenuating age‑related muscle fiber damage [13,14,16,29,30,31,32].

The regenerative capacity of aging muscle is further compromised by functional exhaustion of satellite cells, the resident muscle stem cells responsible for repair and hypertrophy whose activity is governed by both cell‑intrinsic changes and alterations in the surrounding niche microenvironment. Aging of the satellite cell niche is characterized by underproduction of the Notch ligand Delta and overproduction of transforming growth factor‑beta (TGF‑β) and myostatin, leading to excessive activation of TGF‑β/Smad signalling in satellite cells. This shift induces cyclin‑dependent kinase (CDK) inhibitors such as p16 and p21, which block satellite cells from exiting quiescence and entering productive proliferative cycles, thereby impairing regeneration even when growth cues are present. Studies in aged mice show that TGF‑β receptor levels in satellite cells increase approximately three‑ to fourfold with age, compounding the effect of elevated ligand concentrations and creating a potent brake on myogenic responses. Experimentally, ectopic expression of a dominant‑negative TGF‑β receptor II or antibody depletion of TGF‑β from aged serum rescues satellite cell proliferation and differentiation, demonstrating that TGF‑β is a primary, though not sole, inhibitor of regeneration in the aged milieu. Additional complexity arises from dysregulated interleukin‑6 (IL‑6)–Jak2–STAT3 signalling in geriatric muscle, which has been shown to drive satellite cell exhaustion and muscle atrophy following injury, and from altered cross‑talk with fibro‑adipogenic progenitors (FAPs) that normally support satellite cell function by secreting follistatin but become profibrotic and adipogenic in aging and chronic disease. Furthermore, elevated reactive oxygen species (ROS) negatively affect the regenerative capacity of satellite cells during aging, shifting more cells from a reversible quiescent state into irreversible senescence and impairing their proliferation and differentiation into myotubes [35,36,37,38,39,40].

Figure 4. Relationship among oxidative stress, inflammation, and sarcopenia during aging [35]

Mitochondrial dysfunction, oxidative stress, and impaired mitophagy represent a third, interconnected mechanism linking metabolic slowdown to local muscle aging, reduced fiber quality, and functional decline. Age‑related reductions in mitochondrial respiratory capacity, ATP synthesis, and maximal oxygen consumption are independent of fat‑free mass and correlate tightly with preferred walking speed, a defining criterion for sarcopenia and physical frailty suggesting that bioenergetic failure directly constrains muscle performance. The underlying pathophysiology involves a vicious cycle of reactive oxygen species (ROS) production, mitochondrial DNA (mtDNA) mutations and damage, impaired mitochondrial biogenesis regulated by PGC‑1α, and defective mitophagy (selective autophagy of damaged mitochondria), leading to the accumulation of structurally abnormal, dysfunctional mitochondria within aging fibers. Aging muscle exhibits increased mitochondrial hydrogen peroxide (H₂O₂) production, reduced mitochondrial membrane potential, and elevated protein carbonylation, lipid peroxidation, and DNA damage changes that are more pronounced in type II (fast-twitch) fibers, which have lower mitochondrial content and greater susceptibility to oxidative injury and atrophy compared with type I fibers. Pharmacological attenuation of mitochondrial ROS with the mitochondria‑targeted antioxidant SS‑31 reduces oxidative damage and improves mitophagic flux and mitochondrial content in aged mice, though it does not rescue muscle fiber atrophy or strength loss, indicating that while mitochondrial redox dysregulation drives organellar damage and impaired quality control, additional mechanisms likely related to denervation, anabolic resistance, and satellite cell dysfunction, underpin the sarcopenic phenotype. Importantly, structured exercise training stimulates both mitochondrial biogenesis via activation of AMPK and upregulation of PGC-1a and mitophagy, mediated by increased expression of BNIP3, PINK1, and Parkin, thereby restoring mitochondrial turnover and largely negating the effects of aging on muscle oxidative capacity, insulin sensitivity, and physical performance [17,18,19,20,21].

These mechanistic insights highlight critical trade-offs when targeting nutrient-sensing pathways for longevity: interventions that extend lifespan by suppressing mTOR, IGF-1, or caloric intake may simultaneously compromise muscle mass and function if not combined with mechanical loading and adequate protein. Acute pharmacologic inhibition of mTORC1 with rapamycin blocks the contraction‑induced increase in muscle protein synthesis by approximately 40% in humans, demonstrating that mTORC1 activity is essential for exercise‑mediated anabolism in the short term. However, long‑term administration of rapamycin (9–22 months) in aging mice does not reduce muscle mass and in fact mitigates age‑related mitochondrial aging, preserves muscle function, and extends lifespan, with distinct and additive benefits when combined with caloric restriction or exercise training. Importantly, dose matters: low‑dose rapamycin increases muscle cross‑sectional area and preserves fast‑twitch fiber density in aged rats, whereas high‑dose rapamycin offers no such benefit, underscoring the need for context‑specific modulation rather than maximal suppression. Similarly, caloric restriction and protein restriction lower circulating IGF‑1 levels and extend lifespan in rodents, but in humans the effect is largely driven by reduced protein intake rather than total energy restriction, and prolonged severe protein restriction risks muscle loss unless offset by resistance exercise. Mechanistically, patterned, intermittent activation of mTORC1 as occurs with resistance exercise, which induce rapid translocation of mTOR to the cell membrane, dissociation of inhibitory TSC2 from Rheb, and colocalization with translation initiation factors supports muscle hypertrophy and repair, whereas chronic unregulated mTORC1 activation in the absence of mechanical stimuli drives oxidative damage and atrophy. From a clinical standpoint, these findings suggest that the goal in aging muscle is neither maximal suppression nor unchecked activation of anabolic pathways, but rather context-specific, intermittent modulation: sufficient mTORC1 and IGF-1 signalling, synchronized with resistance training and adequate protein intake to support muscle protein synthesis, satellite cell function, and neuromuscular integrity, while avoiding chronic overnutrition and sedentary behaviour that promote insulin resistance, mitochondrial dysfunction, and accelerated fiber loss [14,22,23,24,25,26,,27,28,31,41].

Exercise as a Molecular Rejuvenation Signal

Structured endurance and resistance training induce profound molecular remodelling of aging skeletal muscle at transcriptomic, epigenetic, and mitochondrial levels, in some cases making older trained muscle resemble younger profiles both phenotypically and at the level of gene expression. Landmark human studies demonstrate that six months of resistance training in healthy older adults reverses the expression of 179 age‑associated genes, predominantly those related to mitochondrial function, oxidative phosphorylation, and apoptosis back toward youthful levels, such that post‑exercise transcriptome profiles of older individuals become statistically indistinguishable from those of younger sedentary controls for many genes affected by both age and exercise. Phenotypically, older adults who were 59% weaker than young adults before training improved strength by approximately 50% after six months of progressive resistance exercise, such that they were only 38% weaker than the young comparison group, demonstrating that functional improvement is tightly coupled with transcriptional rejuvenation. Recent work using epigenetic aging clocks extends these findings: late‑life exercise training (progressive weighted wheel running for eight weeks) in aged mice reduced skeletal muscle DNA methylation age by approximately eight weeks, equivalent to roughly 8% of the murine lifespan and attenuated the age-associated shift toward promoter hypermethylation. In humans, sedentary middle‑aged and older women who underwent eight weeks of combined aerobic and strength training showed a significant reduction in epigenetic age of approximately two years, with greater rejuvenation observed in individuals with higher baseline epigenetic age. A controlled trial in younger and older adults demonstrated that 12 weeks of resistance training caused approximately 73% of age‑related differentially methylated CpG sites to approach younger methylation levels, and that recurrent training after a period of detraining increased the responsiveness of both the methylome and transcriptome, providing preliminary evidence for an epigenetic “muscle memory” that enhances adaptability to subsequent training stimuli. Collectively, these data indicate that exercise functions as a partial molecular reprogramming stimulus, sharing a common gene expression signature with Yamanaka factor (OKSM) induction and positioning muscle as uniquely capable of biological rejuvenation despite chronological aging [42,,43,44,45,46,47,48].

Figure 5. Exercise promotes a molecular profile in muscle that is consistent with epigenetic partial reprogramming [42]

Mechanistically, exercise operates as a patterned signal that cyclically activates mTOR and anabolic pathways during and immediately after contraction, while simultaneously stimulating autophagy, mitophagy, and satellite cell activation during recovery, thereby restoring the balance between growth and repair that is dysregulated in sedentary aging muscle. Resistance exercise induces rapid mTORC1 activation via translocation of mTOR to the cell membrane, dissociation of inhibitory TSC2 from Rheb, and colocalization with translation initiation factors, which supports muscle protein synthesis and hypertrophy in a context where mechanical loading provides the essential upstream cue. In contrast to the chronic, maladaptive mTORC1 activation observed in sarcopenic muscle, exercise‑induced mTOR signalling is transient and coupled with activation of AMPK and downregulation of Akt, mTOR, and FoxO3a phosphorylation during periods of energy stress, creating a pulsatile pattern that promotes both anabolic remodelling and autophagic renewal. Controlled studies in aged rodents show that 12 weeks of exercise interventions, particularly resistance exercise significantly upregulate Beclin1 expression, increase the LC3‑II/LC3‑I ratio (indicating active autophagosome formation), downregulate p62 (indicating improved autophagic flux), and activate AMPK while suppressing Akt/mTOR/FoxO3a phosphorylation, collectively rescuing the deficient autophagy observed in sedentary aging muscle. Exercise also stimulates mitophagy by upregulating PINK1, Parkin, and BNIP3, and promotes mitochondrial biogenesis via PGC‑1α and mitochondrial dynamics regulators such as Mfn2 and Drp1, resulting in improved mitochondrial quality control and oxidative capacity. Additionally, exercise activates satellite cells through mechanosensitive pathways including TAZ, which stimulates mTOR signalling via Rheb/Rhebl1 and drives the transition from quiescence (G₀) to the alert state (G_Alert) and proliferation, enhancing regenerative capacity in aging muscle. This cyclical, mechanically coupled activation of anabolic and catabolic programs distinguishes exercise from chronic overnutrition or disuse, positioning it as a unique therapeutic modality that can resolve the mTOR–autophagy paradox in aging muscle [14,15,33,49,50].

A critical distinction exists between volume‑only approaches such as prolonged low‑ to moderate‑intensity aerobic exercise or high‑repetition resistance training to fatigue and targeted resistance training for strength and power, with accumulating evidence that high‑intensity, progressive loading is essential to preserve type II muscle fibers and functional reserve in aging. Type II (fast‑twitch, glycolytic) muscle fibers are preferentially vulnerable to age‑related atrophy, denervation, and loss of satellite cell content, and their decline accounts for much of the reduction in muscle strength, power output, and rapid force generation that defines sarcopenia and predicts falls, disability, and mortality in older adults. In a 12‑week progressive resistance training study in older adults (mean age 71 years), type II fiber cross‑sectional area increased by 23% whereas type I fiber area increased by only 8%, demonstrating a fiber type–specific hypertrophic response that was accompanied by increased type II fiber frequency, reduced grouping of type I fibers (a marker of denervation and motor unit remodeling), and flexible expansion of the myonuclear domain in type II fibers without immediate myonuclear accretion, suggesting that type II myonuclei can upregulate transcriptional activity to support substantial growth. Heavy resistance training has also been shown to reduce the shape factor index (a measure of fiber deformity and irregularity) in type II fibers across all age groups, including the oldest‑old, implying that structural deterioration of these fibers is reversible and that disuse begins driving atrophy and denervation earlier in life than previously recognized. Mechanistically, mechanical tension, imposed by lifting loads at ³60-80% of one-repetition maximum is the primary driver of muscle hypertrophy, activating mechanosensitive pathways, inducing robust increases in muscle protein synthesis that may remain elevated for up to 48 hours, and producing cumulative positive net protein balance when repeated over weeks to months. Progressive overload, systematically increased load, volume or intensity across training cycles is essential to sustain adaptation, as trained muscle exhibits attenuated muscle protein synthesis responses to unchanging stimuli. Dose–response analyses confirm that 12 weeks of resistance training at 80% 1RM can increase isokinetic torque by 16% and knee extensor cross‑sectional area by 11%, effectively reversing approximately 12 years of age‑related decline in strength and muscle size, and that high‑intensity progressive resistance training produces beneficial structural brain changes and improvements in cognitive and motor function alongside muscle adaptation [51,52,53,54,55,56].

These findings coalesce around a conceptual bridge: muscles can be chronologically old but biologically younger when e aging muscle paradox from a fatalistic observation into an actionable opportunity for intervention. Exercise, particularly structured resistance and combined training, mitigates skeletal muscle epigenetic aging, retains or restores a youthful methylome and gene expression profile, and reverses phenotypic markers of aging such as mitochondrial dysfunction, reduced strength, type II fiber atrophy, and impaired regenerative capacity. Meta‑analyses of over 3,000 human skeletal muscle samples reveal that exercise training leads to significant shifts in epigenetic and transcriptomic patterns toward a younger profile, particularly in genes related to muscle structure, metabolism, and mitochondrial function, and that higher cardiorespiratory fitness (VO₂ max) is associated with slower epigenetic aging independent of chronological age. Importantly, the magnitude of these effects is clinically meaningful: exercise can reverse transcriptomic aging substantially, not merely slow its progression, and older adults who train consistently exhibit molecular and functional characteristics that resemble those of younger sedentary individuals, challenging the notion that muscle aging is an irreversible, deterministic process. From a preventive medicine and biohacking perspective, this positions structured, high‑intensity, progressively loaded resistance training, combined with aerobic conditioning to support mitochondrial and cardiovascular health as a first-line, evidence‑based intervention to preserve and restore skeletal muscle as a metabolic organ of longevity, with effects that extend from the molecular level (gene expression, DNA methylation, mitochondrial quality) to the systemic level (insulin sensitivity, functional independence, lifespan extension) [42,44,45,46,47,53].

Nutrition, Protein, and Anabolic Resistance

Older adults exhibit anabolic resistance, a reduced muscle protein synthesis (MPS) response to a given dose of dietary protein and amino acids compared with younger individuals requiring higher relative protein doses and leucine content per meal to achieve similar anabolic stimulation. Comprehensive retrospective analyses estimate that the protein dose necessary to maximally stimulate MPS in older adults is approximately 68% greater than in younger counterparts, resulting in a recommendation of approximately 0.40 g protein per kilogram body mass per meal for older individuals, which translates to roughly 40 g of high‑quality protein or 20 g of essential amino acids (EAAs) to achieve an MPS response that resembles that of younger adults consuming 20–25 g of protein. The branched‑chain amino acid leucine plays a uniquely important role in this process, as it directly activates the mechanistic target of rapamycin complex 1 (mTORC1) signalling in skeletal muscle, thereby stimulating translation initiation and protein synthesis. Studies demonstrate that older adults require 2.5–4 g of leucine per meal, compared with approximately 1 g in younger adults—to surpass the “leucine threshold” necessary to trigger maximal MPS, an amount typically provided by 25–30 g of high‑quality protein such as whey or animal‑derived sources. Importantly, leucine‑enriched protein blends stimulate substantially greater myofibrillar protein synthesis than lower‑leucine blends of equivalent total protein content, both at rest and after resistance exercise, and the magnitude of the acute MPS response correlates positively with the amplitude of the plasma leucine peak after protein ingestion. Mechanistically, anabolic resistance may be mediated in part by hyperphosphorylation of mTORC1 in aging muscle, which paradoxically reduces the muscle’s ability to further phosphorylate and activate mTOR in response to feeding, and by increased splanchnic amino acid uptake and low‑grade inflammation that reduce peripheral amino acid availability and blunt the anabolic signal. National survey data (NHANES) reveal that older adults typically achieve adequate protein intake (25–30 g) at only one meal dinner , while consuming substantially less at breakfast and lunch, a skewed distribution pattern that may fail to optimize 24‑hour MPS and contribute to progressive muscle loss. Epidemiological and intervention‑based studies consistently show that higher habitual protein intake, exceeding 1.0 g per kilogram body mass per day, attenuates the age‑related decline in muscle mass, strength, and functional performance in older adults [57,58,59,60,61,62].

The relationship between protein intake, mTOR activation, and longevity creates a conceptual tension: while chronic suppression of mTOR and IGF‑1 signalling extends lifespan in model organisms, these same pathways are essential for maintaining muscle mass and function in humans, particularly during aging. Emerging evidence suggests that temporal dynamics of mTOR activation rather that absolute magnitude are critical for reconciling these competing goals, such that patterned, intermittent activation of mTOR through resistance exercise and strategic protein intake can support muscle health without the detrimental effects of chronic nutrient overload. The post‑meal anabolic response of MPS has a finite duration of approximately 2–2.5 hours, after which the muscle becomes refractory to further stimulation despite sustained amino acid availability, implying that distributing daily protein intake evenly across multiple meals (3–4 eating occasions with 25–30 g protein each) may maximize cumulative 24‑hour MPS compared with skewed patterns that deliver the majority of protein at a single meal. Controlled feeding studies demonstrate that evenly distributed protein intake increases breakfast‑meal MPS by approximately 40% compared with a skewed pattern, and that adults consuming at least 25 g of protein at two or more meals per day maintain greater muscle mass and strength than those concentrating protein at dinner. However, in the context of energy restriction and when combined with resistance training, the effect of protein distribution on long‑term integrated MPS becomes less pronounced, suggesting that resistance exercise is the primary driver of muscle preservation during caloric deficit, with protein distribution playing a secondary, supportive role. This framework supports a practical strategy of periodic nutrient stimulation, structuring protein intake and resistance training to create transient pulses of mTORC1 activation followed by periods of lower nutrient signalling and enhanced autophagy rather than chronic mTOR suppression, which may extend lifespan in laboratory models but risks accelerating sarcopenia and functional decline in free‑living older adults [25,26,60,63,64,65,66].

From a practical, preventive metabolic health perspective, the priority is to synchronize sufficient protein intake and nutrient density with resistance training rather than pursuing aggressive caloric restriction that can worsen muscle loss, particularly in older adults. Energy restriction in the absence of resistance exercise attenuates the acute MPS response to protein feeding and accelerates muscle loss in overweight and obese older adults, exacerbating sarcopenia and functional decline. However, combining resistance training or, ideally, combined aerobic plus resistance exercise with a balanced distribution of daily protein intake (1.2–1.6 g/kg body weight or higher, distributed across 3–4 meals) restores MPS rates during energy restriction to levels observed during energy balance and is superior to aerobic exercise alone for preserving muscle mass, improving muscle protein synthesis, and enhancing myocellular quality during weight‑loss therapy. Importantly, if total daily protein intake is limited to the Recommended Dietary Allowance (0.8 g/kg, approximately 60 g/day for a 75 kg adult), achieving adequate leucine and total protein at even a single meal (>35–40 g) becomes essential to trigger MPS, whereas higher total intakes (1.2–1.6+ g/kg/day) allow for more flexible, balanced distribution. The strategic framework, therefore, is to prioritize adequate total protein intake, emphasize whole-food, anti-inflammatory dietary patterns (e.g., Mediterranean-style), minimize ultra-processed foods, and synchronize nutrition with structured resistance training, creating a nutritional and training environment that supports patterned mTOR activation, muscle anabolism, and metabolic resilience while avoiding both chronic overnutrition and aggressive under‑nutrition, either of which can accelerate muscle aging and functional decline [59,60,65,66,67,68].

Clinical and Technological Implications

Clinically, translating a muscle‑centric view of aging into practice begins with simple, reproducible assessments that capture muscle quantity, strength, and performance as proxies for muscle quality and biological resilience. Standard tools include handgrip dynamometry to assess muscle strength, chair rise or chair stand tests to evaluate lower‑extremity power, and usual gait speed over 4 meters as a marker of functional capacity, with cut‑offs such as gait speed below 0.8 m/s and low grip strength indicating probable sarcopenia and elevated risk for disability and mortality. Measures of muscle quantity from dual‑energy X‑ray absorptiometry (DXA) or computed tomography (CT), particularly appendicular lean mass indices and cross‑sectional area of thigh or psoas muscles complement functional tests and are incorporated into international consensus definitions of sarcopenia, though accumulating data suggest that muscle strength and performance (grip strength, gait speed, chair stand) are often more predictive of adverse outcomes than lean mass alone. Emerging functional tests such as standing balance, short physical performance batteries, and timed up‑and‑go add granularity to these assessments, enabling clinicians to stratify patients along a spectrum from robust to pre‑sarcopenic to sarcopenic, and to track changes in muscle‑related functional reserve over time [69,70,71,72,73,74,75,76].

Digital health tools and artificial intelligence (AI) offer an opportunity to extend these snapshot assessments into continuous, real‑world monitoring of muscle function, recovery, and metabolic responses. Wearable devices such as accelerometers, inertial measurement units (IMUs), electromyography patches, and smart resistance‑training equipment can capture step counts, gait characteristics, movement velocity, joint angles, time under tension, and session load (e.g. repetitions, sets, bar speed), feeding these data into machine‑learning models that quantify training volume, movement quality, and neuromuscular fatigue in real time. AI‑driven platforms already use heart‑rate variability, sleep metrics, and training logs to forecast recovery status in endurance athletes; similar approaches can be adapted to resistance training to optimize loading, minimize injury risk, and identify early signs of overtraining or functional decline in older adults. Integration of continuous glucose monitoring (CGM) and metabolic wearables with training data enables personalized insights into how specific resistance and power sessions, meal compositions, and recovery strategies affect postprandial glucose excursions, energy availability, and glycemic variability, providing a dynamic readout of the muscle–metabolic interface. In the near term, AI‑enabled coaching systems that combine motion analytics, metabolic signals, and self‑reported outcomes could guide users through strength and power programs tailored to their current capacity, recovery state, and metabolic profile [77,78,79].

Within preventive care and longevity clinics, a muscle‑centric model implies that resistance and power training prescriptions, protein targets, and structured recovery strategies should be considered first‑line interventions rather than optional adjuncts. Practical implementation may involve (1) routine screening of muscle strength (grip dynamometry) and performance (chair stand, gait speed) alongside blood pressure, lipids, and glucose; (2) standardized resistance training protocols emphasizing multi‑joint, progressive loading 2–3 times per week, tailored to baseline strength and comorbidities; (3) explicit protein prescriptions of approximately 1.2–1.6 g/kg/day for older or high‑risk adults, distributed across meals to overcome anabolic resistance; and (4) education around sleep, stress, and recovery practices that support neuromuscular adaptation and mitochondrial health. Combined aerobic plus resistance exercise programs, ideally embedded into multidisciplinary lifestyle interventions, have been shown to preserve muscle mass and function during weight loss in older adults more effectively than aerobic or dietary interventions alone, aligning with the core principle that weight management should protect lean mass rather than sacrifice it [59,68,69,80,81].

Looking forward, multi‑omics, imaging, and AI models are poised to transform muscle‑centric longevity care by enabling individualized prediction of muscle aging trajectories and personalized intervention design. Longitudinal studies integrating genomics, transcriptomics, proteomics, metabolomics, microbiome profiles, and high‑resolution imaging of muscle composition and architecture reveal that aging unfolds in nonlinear “crests” rather than linearly, with periods of accelerated musculoskeletal decline that may be detectable years before clinical frailty. AI frameworks that synthesize these multi‑omic signatures with clinical variables, functional tests, and data streams from wearables and CGM can generate dynamic “muscle aging clocks” and risk stratification tools, forecasting who is likely to experience rapid loss of strength, power, or lean mass and when. Encoder–decoder and latent‑space models combining static individual characteristics (genetics, early‑life exposures) with longitudinal imaging and wearable data may allow clinicians to simulate the effects of different exercise, nutrition, and pharmacologic regimens on future muscle function, shifting practice from reactive management of sarcopenia to proactive, continuously updated prevention. In this vision, muscle metrics become central features in biologic aging clocks and clinical decision‑support systems, operationalizing the concept that maintaining strong, metabolically healthy muscle is not merely a by‑product of good health, but a modifiable driver of extended health span [82,83,84,85].

Conclusion

The aging muscle paradox encapsulates the idea that skeletal muscle in later life can be both atrophic and hyper‑signalled for growth, exhibiting chronically elevated mTORC1 and growth cues alongside suppressed autophagy, impaired regeneration, and declining mitochondrial quality, yet remains uniquely capable of molecular and functional rejuvenation when exposed to the right mechanical and metabolic stimuli. In this framework, sarcopenic muscle is not a uniformly “dead” tissue but a maladapted one: metabolically vulnerable and structurally compromised, but still responsive to targeted resistance training, aerobic conditioning, and nutritional strategies that restore the balance between protein synthesis and degradation, promote autophagic and mitophagic renewal, and re‑engage satellite cell and neuromuscular junction plasticity.

Recognizing skeletal muscle as a metabolic and endocrine organ of longevity reframes its preservation as one of the most actionable levers to slow metabolic aging and extend health span, rather than a secondary aesthetic or performance goal. Maintaining and improving muscle mass, strength, and quality through progressive resistance training, adequate protein and micronutrient intake, and recovery that supports mitochondrial and hormonal health directly influences insulin sensitivity, glycemic stability, visceral fat accumulation, inflammatory tone, and functional reserve, all of which converge on cardiometabolic risk and late‑life disability. In practical terms, this means that interventions which keep muscle “young”, strong, oxidative, and flexible in substrate use can delay or blunt emergence of multimorbidity, even in the presence of other age-related changes.

Against this backdrop, there is a strong rationale to shift from fat‑centric and glucose‑centric counselling toward a muscle‑centric model of preventive medicine and biohacking, especially in midlife when muscle decline is still largely modifiable. Traditional clinical and wellness narratives often prioritize weight, BMI, or fasting glucose as primary targets, inadvertently tolerating or even accelerating muscle loss through chronic calorie restriction, excessive steady‑state cardio, or under‑emphasis on protein and strength training. A muscle‑centric paradigm instead treats lean mass, strength, power, and muscle metabolic health as upstream determinants: if skeletal muscle is preserved and metabolically fit, adiposity, glycemic control, and many downstream biomarkers tend to normalize or become more tractable.

The practical implication is a clear call to action: integrate muscle‑focused exercise, nutrition, and technology‑enabled monitoring into routine care and personal biohacking frameworks, explicitly positioning skeletal muscle not only as a marker of aging but as a modifiable driver of biological youth. Clinically, this includes systematically assessing muscle function (grip strength, chair rise, gait speed), embedding resistance and power training prescriptions into primary care and longevity programs, and aligning dietary guidance around protein adequacy and mitochondrial support rather than calorie minimization alone. On the technology side, combining wearables, strength‑tracking apps, and metabolic sensors such as CGM or indirect calorimetry can help individualize training loads, recovery windows, and nutritional strategies, turning the muscle aging paradox into a continuous feedback loop for intervention rather than a late‑stage diagnosis. Framed this way, “training muscle for longevity” becomes a core therapeutic strategy, one that aligns molecular aging biology with everyday clinical practice and patient behaviour, transforming skeletal muscle from a passive casualty of aging into an active instrument for preserving youth.

Reference

Honka MJ, Latva-Rasku A, Bucci M, Virtanen KA, Hannukainen JC, Kalliokoski KK, et al. Insulin-stimulated glucose uptake in skeletal muscle, adipose tissue and liver: a positron emission tomography study. European Journal of Endocrinology [Internet]. 2018 Mar 7;178(5):523–31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920018/
Merz KE, Thurmond DC. Role of Skeletal Muscle in Insulin Resistance and Glucose Uptake. Comprehensive Physiology. 2020 Jul;10(3):785–809.
Ramos PA, Lytle KA, Delivanis D, Nielsen S, LeBrasseur NK, Jensen MD. Insulin-Stimulated Muscle Glucose Uptake and Insulin Signaling in Lean and Obese Humans. The Journal of Clinical Endocrinology & Metabolism. 2020 Dec 31;
Jensen J, Rustad PI, Kolnes AJ, Lai YC. The Role of Skeletal Muscle Glycogen Breakdown for Regulation of Insulin Sensitivity by Exercise. Frontiers in Physiology [Internet]. 2011 Dec 30;2(112). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248697/
DeFronzo RA, Tripathy D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care. 2009 Oct 29;32(suppl_2):S157–63.
Lopez-Jaramillo P, Lopez-Lopez JP, Tole MC, Cohen DD. Muscular Strength in Risk Factors for Cardiovascular Disease and Mortality: A Narrative Review. Anatolian Journal of Cardiology [Internet]. 2022 Aug 1;26(8):598–607. Available from: https://pubmed.ncbi.nlm.nih.gov/35924286/
Hsieh MF, Wang SI, Hsieh HF, Huang MZ, Wang HH. Low muscle strength and mortality: Key risk factors in the National Health and Nutrition Examination Survey retrospective cohort study. Medicine [Internet]. 2025 Oct 17 [cited 2026 Jan 29];104(42):e45284. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12537101/
Rezuş E, Burlui A, Cardoneanu A, Rezuş C, Codreanu C, Pârvu M, et al. Inactivity and Skeletal Muscle Metabolism: A Vicious Cycle in Old Age. International Journal of Molecular Sciences. 2020 Jan 16;21(2):592.
Wang Y, Luo DH, Liu J, Yu SB, Jiang B, Jiang H. Low skeletal muscle mass index and all-cause mortality risk in adults: A systematic review and meta-analysis of prospective cohort studies. PLOS ONE. 2023 Jun 7;18(6):e0286745–5.
Chen Y, Wu J. Aging-Related Sarcopenia: Metabolic Characteristics and Therapeutic Strategies. Aging and disease. 2024;0.
[Internet]. [cited 2026 Jan 29]. Available from: https://www.liebertpub.com/doi/10.1089/ict.2024.82391.gl?doi=10.1089/ict.2024.82391.gl
Bahls M, Kavousi M, Bakker EA, Kränkel N, Baurecht H, Timmermans EJ, et al. Physical activity and mortality: Towards healthspan-oriented metrics and outcomes. A scientific statement from the European Association of Preventive Cardiology (EAPC) of the ESC. European Journal of Preventive Cardiology. 2025 Sept 8; doi:10.1093/eurjpc/zwaf578
Choy SM, Goh KY, Lee WX, Jiang W, Gou Q, Gopal Krishnan PD, et al. Exercise suppresses DEAF1 to normalize mTORC1 activity and reverse muscle aging. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2025 Feb;122(48):e2508893122. Available from: https://pubmed.ncbi.nlm.nih.gov/41284871/
Ham DJ, Börsch A, Lin S, Thürkauf M, Weihrauch M, Reinhard JR, et al. The neuromuscular junction is a focal point of mTORC1 signaling in sarcopenia. Nature Communications [Internet]. 2020 Sep 9;11(1):4510. Available from: https://pubmed.ncbi.nlm.nih.gov/32908143/
Tang H, Inoki K, Brooks SV, Okazawa H, Lee M, Wang J, et al. mTORC1 underlies age‐related muscle fiber damage and loss by inducing oxidative stress and catabolism. Aging Cell. 2019 Mar 29;18(3):e12943.
Kaiser MS, Milan G, Ham DJ, Lin S, Oliveri F, Chojnowska K, et al. Dual roles of mTORC1-dependent activation of the ubiquitin-proteasome system in muscle proteostasis. Communications biology. 2022 Oct 27;5(1).
Chai S, Zhang N, Cui C, Bao Z, Wang Q, Lin W, et al. Systematic review of mitochondrial dysfunction and oxidative stress in aging: A focus on neuromuscular junctions. Neural Regeneration Research. 2025 Apr 29;21(5):1947–60.
Marzetti E, Calvani R, Cesari M, Buford TW, Lorenzi M, Behnke BJ, et al. Mitochondrial dysfunction and sarcopenia of aging: From signaling pathways to clinical trials. The International Journal of Biochemistry & Cell Biology. 2013 Oct;45(10):2288–301.
Kang C, Li Ji L. Role of PGC-1α signaling in skeletal muscle health and disease. Annals of the New York Academy of Sciences. 2012 Oct;1271(1):110–7.
Geng T, Li P, Okutsu M, Yin X, Kwek J, Zhang M, et al. PGC-1α plays a functional role in exercise-induced mitochondrial biogenesis and angiogenesis but not fiber-type transformation in mouse skeletal muscle. American Journal of Physiology-Cell Physiology. 2010 Mar;298(3):C572–9.
Seo DY, Lee SR, Kim N, Ko KS, Rhee BD, Han J. Age-related changes in skeletal muscle mitochondria: the role of exercise. Integrative Medicine Research. 2016 Sep;5(3):182–6.
Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell [Internet]. 2008 Oct [cited 2020 May 3];7(5):681–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673798/pdf/nihms95561.pdf
Kazemi A, Speakman JR, Soltani S, Djafarian K. Effect of calorie restriction or protein intake on circulating levels of insulin like growth factor I in humans: A systematic review and meta-analysis. Clinical Nutrition. 2020 Jun;39(6):1705–16.
Song Z, Moore DR, Hodson N, Ward C, Dent JR, O’Leary MF, et al. Resistance exercise initiates mechanistic target of rapamycin (mTOR) translocation and protein complex co-localisation in human skeletal muscle. Scientific Reports [Internet]. 2017 Jul 10;7(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504043/
Sharples AP, Hughes DC, Deane CS, Saini A, Selman C, Stewart CE. Longevity and skeletal muscle mass: the role of IGF signalling, the sirtuins, dietary restriction and protein intake. Aging Cell. 2015 Apr 10;14(4):511–23.
Barclay RD, Burd NA, Tyler C, Tillin NA, Mackenzie RW. The Role of the IGF-1 Signaling Cascade in Muscle Protein Synthesis and Anabolic Resistance in Aging Skeletal Muscle. Frontiers in Nutrition. 2019 Sep 10;6.
gov. 2026 [cited 2026 Jan 29]. Available from: https://clinicaltrials.gov/study/NCT05414292
Drummond MJ, Fry CS, Glynn EL, Dreyer HC, Dhanani S, Timmerman KL, et al. Rapamycin administration in humans blocks the contraction-induced increase in skeletal muscle protein synthesis. The Journal of Physiology. 2009 Mar 31;587(7):1535–46.
Han X, Goh KY, Lee WX, Choy SM, Tang HW. The Importance of mTORC1-Autophagy Axis for Skeletal Muscle Diseases. International Journal of Molecular Sciences [Internet]. 2023 Jan 1 [cited 2023 Oct 8];24(1):297. Available from: https://www.mdpi.com/1422-0067/24/1/297
Welcome To Zscaler Directory Authentication [Internet]. Nature.com. 2026 [cited 2026 Jan 30]. Available from: https://www.nature.com/articles/s41598-024-58716-1
Tang H, Inoki K, Brooks SV, Okazawa H, Lee M, Wang J, et al. mTORC1 underlies age‐related muscle fiber damage and loss by inducing oxidative stress and catabolism. Aging Cell. 2019 Mar 29;18(3):e12943.
Castets P, Frank S, Sinnreich M, Rüegg MA. “Get the Balance Right”: Pathological Significance of Autophagy Perturbation in Neuromuscular Disorders. Journal of Neuromuscular Diseases. 2016 May 27;3(2):127–55.
Zeng Z, Liang J, Wu L, Zhang H, Lv J, Chen N. Exercise-Induced Autophagy Suppresses Sarcopenia Through Akt/mTOR and Akt/FoxO3a Signal Pathways and AMPK-Mediated Mitochondrial Quality Control. Frontiers in Physiology. 2020 Nov 2;11.
Wang C, Liang J, Ren Y, Huang J, Jin B, Wang G, et al. A Preclinical Systematic Review of the Effects of Chronic Exercise on Autophagy-Related Proteins in Aging Skeletal Muscle. Frontiers in Physiology [Internet]. 2022 Jul 14;13:930185. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329943/
Chen M, Wang Y, Deng S, Lian Z, Yu K. Skeletal muscle oxidative stress and inflammation in aging: Focus on antioxidant and anti-inflammatory therapy. Frontiers in Cell and Developmental Biology. 2022 Aug 30;10.
Farup J, Madaro L, Puri PL, Mikkelsen UR. Interactions between muscle stem cells, mesenchymal-derived cells and immune cells in muscle homeostasis, regeneration and disease. Cell Death & Disease. 2015 Jul;6(7):e1830–0.
Jeong J, Conboy MJ, Conboy IM. Pharmacological inhibition of myostatin/TGF-β receptor/pSmad3 signaling rescues muscle regenerative responses in mouse model of type 1 diabetes. Acta Pharmacologica Sinica. 2013 Jun 17;34(8):1052–60.
Blau HM, Cosgrove BD, Ho ATV. The central role of muscle stem cells in regenerative failure with aging. Nature Medicine. 2015 Aug;21(8):854–62.
Carlson ME, Conboy MJ, Hsu M, Barchas L, Jeong J, Agrawal A, et al. Relative roles of TGF-β1 and Wnt in the systemic regulation and aging of satellite cell responses. Aging Cell. 2009 Dec;8(6):676–89.
Meiliana A, Dewi NM, Wijaya A. Molecular Regulation and Rejuvenation of Muscle Stem (Satellite) Cell Aging. The Indonesian Biomedical Journal. 2015 Aug 1;7(2):73.
Synergistic Effects of Rapamycin and Exercise for Maximizing Muscular Strength | Healthspan [Internet]. Healthspan. Healthspan website; 2025 [cited 2026 Jan 30]. Available from: https://www.gethealthspan.com/research/article/rapamycin-and-muscle-preservation
Jones RG, Dimet‐Wiley A, Haghani A, da Silva FM, Brightwell CR, Lim S, et al. A molecular signature defining exercise adaptation with ageing and in vivopartial reprogramming in skeletal muscle. The Journal of Physiology. 2023 Jan 24;601(4):763–82.
Pillon NJ, Gabriel BM, Dollet L, Smith JAB, Sardón Puig L, Botella J, et al. Transcriptomic profiling of skeletal muscle adaptations to exercise and inactivity. Nature Communications. 2020 Jan 24;11(1).
Kawamura T, Higuchi M, Radak Z, Taki Y. Exercise as a geroprotector: focusing on epigenetic aging. Aging. 2025 Jul 8;
Melov S, Tarnopolsky MA, Beckman K, Felkey K, Hubbard A. Resistance Exercise Reverses Aging in Human Skeletal Muscle. Wenner P, editor. PLoS ONE [Internet]. 2007 May 23;2(5):e465. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1866181/
Exercise may actually reverse your body’s aging clock [Internet]. ScienceDaily. 2025. Available from: https://www.sciencedaily.com/releases/2025/08/250831010510.htm
Murach KA, Dimet-Wiley AL, Wen Y, Brightwell CR, Latham CM, Dungan CM, et al. Late-life exercise mitigates skeletal muscle epigenetic aging. Aging Cell [Internet]. 2022 Jan 1;21(1):e13527. Available from: https://pubmed.ncbi.nlm.nih.gov/34932867/#:~:text=The epigenetic age of muscle
Blocquiaux S, Ramaekers M, Ruud Van Thienen, Henri Nielens, Christophe Delecluse, Katrien De Bock, et al. Recurrent training rejuvenates and enhances transcriptome and methylome responses in young and older human muscle. JCSM rapid communications. 2021 Oct 17;5(1):10–32.
Kim KM, Yoo GD, Heo W, Oh HT, Park J, Shin S, et al. TAZ stimulates exercise‐induced muscle satellite cell activation via Pard3–p38 MAPK–TAZ signalling axis. Journal of Cachexia Sarcopenia and Muscle. 2023 Nov 3;14(6):2733–46.
Chatzinikita E, Maridaki M, Palikaras K, Koutsilieris M, Philippou A. The Role of Mitophagy in Skeletal Muscle Damage and Regeneration. Cells [Internet]. 2023 Feb 24 [cited 2023 Apr 22];12(5):716. Available from: https://pubmed.ncbi.nlm.nih.gov/36899852/
Moro T, Brightwell CR, Volpi E, Rasmussen BB, Fry CS. Resistance exercise training promotes fiber type-specific myonuclear adaptations in older adults. Journal of Applied Physiology (Bethesda, Md: 1985) [Internet]. 2020 Apr 1;128(4):795–804. Available from: https://pubmed.ncbi.nlm.nih.gov/32134710/
Evans W. Functional and Metabolic Consequences of Sarcopenia. The Journal of Nutrition [Internet]. 1997 May;127(5):998S1003S. Available from: https://academic.oup.com/jn/article/127/5/998S/4724150
Borde R, Hortobágyi T, Granacher U. Dose–Response Relationships of Resistance Training in Healthy Old Adults: A Systematic Review and Meta-Analysis. Sports Medicine [Internet]. 2015 Sep 29;45(12):1693–720. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656698/
Van Every DW, Lees MJ, Wilson B, Nippard J, Phillips SM. Load-induced human skeletal muscle hypertrophy: Mechanisms, myths, and misconceptions. Journal of Sport and Health Science [Internet]. 2025 Nov 21;101104. Available from: https://www.sciencedirect.com/science/article/pii/S2095254625000869
Izquierdo M, Merchant RA, Morley JE, Anker SD, Aprahamian I, Arai H, et al. International Exercise Recommendations in Older Adults (ICFSR): Expert Consensus Guidelines. The Journal of Nutrition, Health & Aging [Internet]. 2021 Jul;25(7):824–53. Available from: https://link.springer.com/article/10.1007/s12603-021-1665-8
Attia P. Resistance training partially reverses some of the hallmarks of aging type II muscle fibers [Internet]. Peter Attia. 2024 [cited 2026 Jan 30]. Available from: https://peterattiamd.com/muscle-fiber-shape-and-resistance-training/
Volpi E. Is leucine content in dietary protein the key to muscle preservation in older women? The American Journal of Clinical Nutrition. 2018 Feb 1;107(2):143–4.
Wall BT, Cermak NM, van Loon LJC. Dietary Protein Considerations to Support Active Aging. Sports Medicine. 2014 Oct 30;44(S2):185–94.
Deutz NEP, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy-Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. Clinical Nutrition [Internet]. 2014 Dec;33(6):929–36. Available from: https://www.espen.org/files/PIIS0261561414001113.pdf
Layman DK. Impacts of protein quantity and distribution on body composition. Frontiers in nutrition. 2024 May 3;11.
Deane CS, Cox J, Atherton PJ. Critical variables regulating age-related anabolic responses to protein nutrition in skeletal muscle. Frontiers in Nutrition. 2024 Aug 6;11.
Trabal J, Forga M, Leyes P, Torres F, Rubio J, Prieto E, et al. Effects of free leucine supplementation and resistance training on muscle strength and functional status in older adults: a randomized controlled trial. Clinical Interventions in Aging. 2015 Apr;713.
Mamerow MM, Mettler JA, English KL, Casperson SL, Arentson-Lantz E, Sheffield-Moore M, et al. Dietary Protein Distribution Positively Influences 24-h Muscle Protein Synthesis in Healthy Adults. The Journal of Nutrition. 2014 Jan 29;144(6):876–80.
mTOR and Longevity: Rethinking the Role of Periodic Nutrient Stimulation [Internet]. GlobalRPH. 2025 [cited 2026 Jan 30]. Available from: https://globalrph.com/2025/07/mtor-and-longevity-rethinking-the-role-of-periodic-nutrient-stimulation/
Hudson JL, Bergia RE, Campbell WW. Protein Distribution and Muscle-Related Outcomes: Does the Evidence Support the Concept? Nutrients. 2020 May 16;12(5):1441.
Murphy CH, Shankaran M, Churchward-Venne TA, Mitchell CJ, Kolar NM, Burke LM, et al. Effect of resistance training and protein intake pattern on myofibrillar protein synthesis and proteome kinetics in older men in energy restriction. The Journal of Physiology. 2018 Apr 17;596(11):2091–120.
Papadopoulou SK, Detopoulou P, Voulgaridou G, Tsoumana D, Spanoudaki M, Sadikou F, et al. Mediterranean Diet and Sarcopenia Features in Apparently Healthy Adults over 65 Years: A Systematic Review. Nutrients. 2023 Feb 22;15(5):1104.
Colleluori G, Aguirre L, Phadnis U, Fowler K, Armamento-Villareal R, Sun Z, et al. Aerobic Plus Resistance Exercise in Obese Older Adults Improves Muscle Protein Synthesis and Preserves Myocellular Quality Despite Weight Loss. Cell Metabolism [Internet]. 2019 Aug 6;30(2):261-273.e6. Available from: https://reader.elsevier.com/reader/sd/pii/S1550413119303110?token=F8504C915C44765220A7564FDE3FC1D7396B4711C1A2CDD023074B85ACD30DF9386216C4474CD2832BACED749017C9EB&originRegion=us-east-1&originCreation=20220125194027
Sardeli A, Komatsu T, Mori M, Gáspari A, Chacon-Mikahil M. Resistance Training Prevents Muscle Loss Induced by Caloric Restriction in Obese Elderly Individuals: A Systematic Review and Meta-Analysis. Nutrients. 2018 Mar 29;10(4):423.
Hallajzadeh J, Yousefi Tanha P, Azadnia A, Wong A, Moradi S. The association of ultra-processed foods and risk of sarcopenia among community-dwelling older adults. BMC Geriatrics [Internet]. 2025 Dec 5 [cited 2026 Jan 30];25(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12681142/
Westbury LD, Harvey NC, Beaudart C, Olivier Bruyère, Cauley JA, Cawthon P, et al. Predictive value of sarcopenia components for all-cause mortality: findings from population-based cohorts. Aging Clinical and Experimental Research. 2024 Jun 6;36(1).
Ackermans LLGC, Rabou J, Basrai M, Schweinlin A, Bischoff SC, Cussenot O, et al. Screening, diagnosis and monitoring of sarcopenia: When to use which tool? Clinical Nutrition ESPEN. 2022 Apr;48:36–44
Yu SCY, Khow KSF, Jadczak AD, Visvanathan R. Clinical Screening Tools for Sarcopenia and Its Management. Current Gerontology and Geriatrics Research [Internet]. 2016;2016:1–10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757731/
Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis , WRITING GROUP FOR THE EUROPEAN WORKING GROUP ON SARCOPENIA IN OLDER PEOPLE 2 (EWGSOP2), AND THE EXTENDED GROUP FOR EWGSOP2. Age and Ageing [Internet]. 2018 [cited 2026 Jan 30];0:1–16. Available from: https://sbgg.org.br/informativos/23-11-18/1-sarcopenia.pdf
Martone AM, Marzetti E, Calvani R, Picca A, M. Tosato, Bernabei R, et al. Assessment of sarcopenia: from clinical practice to research. JOURNAL OF GERONTOLOGY AND GERIATRICS [Internet]. 2019 [cited 2026 Jan 30];67:39–45. Available from: https://www.jgerontology-geriatrics.com/article/view/105
Huang CH, Peng LN, Chen LK. Muscle Strength Predicting Health Outcomes of Older Adults: A Narrative Review. Aging Medicine and Healthcare. 2019 Sep 24;10(3):96–9.
de Beukelaar TT, Mantini D. Monitoring Resistance Training in Real Time with Wearable Technology: Current Applications and Future Directions. Bioengineering [Internet]. 2023 Sep 1;10(9):1085. Available from: https://www.mdpi.com/2306-5354/10/9/1085
Grivas GV, Safari K. Artificial Intelligence in Endurance Sports: Metabolic, Recovery, and Nutritional Perspectives. Nutrients [Internet]. 2025 Oct 13;17(20):3209–9. Available from: https://www.mdpi.com/2072-6643/17/20/3209?utm_
Xianyong S, Mishra DK, Özcan ÖÖ, Karahan M, Panpan T, Zhongshan X, et al. Wearable smart sensors integration with AI and machine learning for tracking human health. Biosensors and Bioelectronics: X [Internet]. 2025 Nov 12;27:100711. Available from: https://www.sciencedirect.com/science/article/pii/S2590137025001384
Strasser B, Volaklis K, Fuchs D, Burtscher M. Role of Dietary Protein and Muscular Fitness on Longevity and Aging. Aging and Disease. 2018;9(1):119.
Morgan PT, Witard OC, Grith Højfeldt, Church DD, Breen L. Dietary protein recommendations to support healthy muscle ageing in the 21st Century and beyond: considerations and future directions. Proceedings of the Nutrition Society. 2023 Oct 11;1–32.
Shen X, Wang C, Zhou X, Zhou W, Hornburg D, Wu S, et al. Nonlinear dynamics of multi-omics profiles during human aging. Nature Aging [Internet]. 2024 Aug 14;1–16. Available from: https://www.nature.com/articles/s43587-024-00692-2
Khalaf F, Barayan D, Saldanha S, Jeschke MG. Metabolaging: a new geroscience perspective linking aging pathologies and metabolic dysfunction. Metabolism [Internet]. 2025 Feb 11;166:156158. Available from: https://www.sciencedirect.com/science/article/pii/S0026049525000277#s0135
Littlewood K, Jasleen Gegic, Hickman M, Henson RCJ, Bishop JR, Kershaw T, et al. Metabolic dysfunction over a life course key to healthy ageing inequality. Aging Clinical and Experimental Research. 2025 Jun 23;37(1).
Diao X, Zhang H, Wang S, Zhang Q, Wang Z. Bridging ancient wisdom and modern technology: an AI and multi-omics framework for three causes tailored treatment in personalized medicine. Frontiers in Molecular Biosciences [Internet]. 2025 Dec 18 [cited 2026 Jan 30];12. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12756077/